ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -15 مورد

Phenylephrine (systemic): Drug information

Phenylephrine (systemic): Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Phenylephrine (systemic): Patient drug information" and "Phenylephrine (systemic): Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Biorphen;
  • FT Nasal Decongestant PE [OTC];
  • Immphentiv;
  • Medi-Phenyl [OTC];
  • Non-Pseudo Sinus Decongestant [OTC];
  • Sudafed PE Childrens [OTC];
  • Sudafed PE Sinus Congestion [OTC];
  • Sudanyl PE [OTC];
  • Vazculep
Brand Names: Canada
  • Neo-Synephrine [DSC]
Pharmacologic Category
  • Alpha-Adrenergic Agonist
Dosing: Adult
Hypotension or shock

Hypotension or shock: Note: Not recommended for septic shock except in the following circumstances: 1) when norepinephrine (preferred first-line agent) is associated with serious arrhythmias; 2) when cardiac output is known to be high and BP persistently low; or 3) used as salvage therapy when the combination of vasopressor/inotropic agents and low-dose vasopressin fail to achieve target mean arterial pressure (MAP) (Ref). In general, maintain goal MAP (eg, ~65 mm Hg); consider use if patient is in shock or has hypoperfusion during or after fluid resuscitation (Ref). Institutional protocols may vary with weight-based or non–weight-based dose regimens.

Septic shock and other vasodilatory shock states (alternative agent):

Weight-based dosing: Continuous infusion: IV: Initial dose: 0.5 to 2 mcg/kg/minute; titrate to desired MAP; usual dosage range: 0.25 to 5 mcg/kg/minute. Doses up to 9.1 mcg/kg/minute have been reported (Ref).

Non–weight-based dosing (based on ~80 kg patient): Continuous infusion: IV: Initial dose: 40 to 160 mcg/minute; titrate to desired MAP; usual dosage range: 20 to 400 mcg/minute. Doses up to ~730 mcg/minute have been reported (doses calculated and rounded for an 80 kg patient according to weight-based dosing using the referenced sources (Ref)).

Cardiogenic shock: Note: Depending on hemodynamic variables, may consider for vasoactive management of cardiogenic shock due to aortic stenosis, mitral stenosis, or hypertrophic cardiomyopathy with left ventricular outflow tract obstruction (Ref).

Continuous infusion: IV: 0.1 to 10 mcg/kg/minute; titrate to clinical end point (Ref).

Hypotension during anesthesia

Hypotension during anesthesia:

IV bolus: Initial: 40 to 100 mcg/dose; may repeat every 1 to 2 minutes as needed; titrate to clinical end point; maximum total dose: 200 mcg.

Continuous infusion: IV: Initial dose: 10 to 35 mcg/minute; titrate to clinical end point; maximum dose: 200 mcg/minute.

Nasal congestion

Nasal congestion: Oral: OTC labeling: 10 mg every 4 hours as needed for ≤7 days (maximum: 60 mg/24 hours).

Priapism, acute ischemic

Priapism, acute ischemic (off-label use): Note: The optimal dosing, frequency, and method of administration has not been established.

Intracavernous (off-label route): 100 to 500 mcg every 5 minutes or greater as needed for up to 1 hour (using a concentration of 100 to 500 mcg/mL); if used with aspiration/irrigation, then aspiration should be performed before administration of phenylephrine (Ref).

Dosing: Kidney Impairment: Adult

Mild to severe impairment: There are no dosage adjustments provided in the manufacturer's labeling.

End-stage kidney disease: There are no dosage adjustments provided in the manufacturer's labeling; dose-response data indicate increased responsiveness; lower initial doses may be required.

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; dose-response data indicate decreased responsiveness; higher doses may be required.

Dosing: Obesity: Adult

The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.

Class 1, 2, and 3 obesity (BMI ≥30 kg/m2):

Continuous infusion: IV: If institution uses weight-based dosing, use ideal body weight for initial weight-based dose calculations, then titrate to hemodynamic effect and clinical response (Ref). If institution uses nonweight-based dosing for vasoactive agents, continue with this approach. During therapy, clinicians should not change dosing weight from one weight metric to another (ie, ideal body weight to/from actual body weight or weight-based dosing to/from nonweight-based dosing) (Ref). Refer to adult dosing for indication specific doses.

Rationale for recommendations: There is a paucity of studies evaluating the influence of obesity on phenylephrine dosing or pharmacokinetics. Observational studies, including phenylephrine, epinephrine, and norepinephrine, suggest nonweight-based dosing strategies may result in lower overall cumulative dose requirements and increased drug exposure to second line agents in some patients and may not be advantageous in time to achieving hemodynamic stability (Ref). However, it is difficult to show outcome differences between weight-based and nonweight-based dosing because of dose titration to target BP, particularly in the context of retrospective studies. Furthermore, there is substantial variability in response in critically ill patients, irrespective of weight. Due to the short onset of action and small Vd, rapid titration to clinical effect after initial dosing is possible (Ref).

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Phenylephrine (systemic): Pediatric drug information")

Note: Dosing presented in both mg (oral) and mcg (parenteral); use caution when ordering and dispensing.

Nasal congestion

Nasal congestion: Oral:

Children 4 to 5 years: 2.5 mg every 4 hours; maximum daily dose: 15 mg in 24 hours.

Children 6 to 11 years: 5 mg every 4 hours; maximum daily dose: 30 mg in 24 hours.

Children ≥12 years and Adolescents: 10 mg every 4 hours; maximum daily dose: 60 mg in 24 hours.

Hypotension, low cardiac output

Hypotension, low cardiac output: Limited data available: Infants, Children, and Adolescents:

IM, SubQ: 100 mcg/kg/dose every 1 to 2 hours as needed; maximum dose: 5,000 mcg/dose (Ref).

IV bolus: 5 to 20 mcg/kg/dose every 10 to 15 minutes as needed (Ref); initial dose should not exceed 500 mcg/dose.

Continuous IV infusion: Usual initial dose: 0.1 to 0.5 mcg/kg/minute; titrate to desired response (Ref); in cases of shock or intraoperative hypotension, doses up to 2 mcg/kg/minute have been reported (Ref); for management of infundibular spasm (tet spell), even higher doses up to 5 mcg/kg/minute may be required (Ref).

Hypotension during spinal anesthesia

Hypotension during spinal anesthesia: IM, SubQ: Infants, Children, and Adolescents: 44 to 88 mcg/kg/dose; maximum dose: 500 mcg.

Dosing: Kidney Impairment: Pediatric

Mild to severe impairment: There are no dosage adjustments provided in the manufacturer's labeling.

End-stage renal disease: There are no dosage adjustments provided in the manufacturer's labeling. Based on dose-response data, a lower initial dose is recommended.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions are derived from product labeling for IV use, unless otherwise specified.

Postmarketing:

Cardiovascular: Atrioventricular block, bradycardia, cardiac arrhythmia, cardiomyopathy (oral; takotsubo) (Zlotnick 2012), chest pain, hypertension, hypertensive crisis, ischemia, ischemic heart disease, low cardiac output, premature ventricular contractions, reflex bradycardia

Dermatologic: Diaphoresis, pallor, piloerection, pruritus

Gastrointestinal: Epigastric pain, ischemic colitis (oral) (El-Alali 2020), nausea, vomiting

Hypersensitivity: Hypersensitivity reaction (sulfite sensitivity; including anaphylaxis) (Pathan 2024))

Local: Localized blanching

Nervous system: Cerebrovascular accident (IV, oral; including cerebral hemorrhage) (Tark 2014), excitability, headache, nervousness, paresthesia, tremor

Neuromuscular & skeletal: Neck pain

Ophthalmic: Blurred vision

Respiratory: Dyspnea, pulmonary edema, rales

Contraindications

Immphentiv: Hypersensitivity to phenylephrine or any component of the formulation.

OTC labeling (Oral): When used for self-medication: Use with or within 14 days of monoamine oxidase inhibitor therapy.

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Warnings/Precautions

Concerns related to adverse effects:

• Cardiovascular effects: IV use of phenylephrine may cause severe bradycardia (likely baroreflex mediated) and reduced cardiac output due to an increase in cardiac afterload especially in patients with preexisting cardiac dysfunction (Goertz 1993; Yamazaki 1982). May also precipitate angina in patients with severe coronary artery disease and increase pulmonary arterial pressure. Use with caution in patients with preexisting bradycardia, partial heart block, myocardial disease, or severe coronary artery disease. Avoid or use with extreme caution in patients with heart failure or cardiogenic shock; increased systemic vascular resistance may significantly reduce cardiac output. Avoid use in patients with hypertension (contraindicated in severe hypertension); monitor BP closely and adjust infusion rate. May also cause excessive peripheral and visceral vasoconstriction and ischemia to vital organs, particularly in patients with extensive peripheral vascular disease.

• Extravasation: IV administration: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.

Disease-related concerns:

• Acidosis: Acidosis may reduce the efficacy of phenylephrine; correct acidosis during use of phenylephrine.

• Autonomic dysfunction: Patients with autonomic dysfunction (eg, spinal cord injury) may exhibit an exaggerated increase in BP response to phenylephrine.

Concurrent drug therapy issues:

• Monoamine oxidase inhibitors: Use with extreme caution in patients taking monoamine oxidase inhibitors; hypertension may result from concurrent use.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.

• Oral: When used for self-medication (OTC), use with caution in patients with asthma, bowel obstruction/narrowing, hyperthyroidism, diabetes mellitus, cardiovascular disease, ischemic heart disease, hypertension, increased intraocular pressure, prostatic hyperplasia, or in older adults. Notify health care provider if symptoms do not improve within 7 days or are accompanied by fever. Discontinue and contact health care provider if nervousness, dizziness, or sleeplessness occur.

• Sulfites: Some products contain sulfites, which may cause allergic reactions in susceptible individuals.

Other warnings/precautions:

• Appropriate use: When used IV in patients who are hypotensive, assure adequate circulatory volume to minimize need for vasoconstrictors.

Warnings: Additional Pediatric Considerations

Safety and efficacy for the use of cough and cold products in pediatric patients <4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported. Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA does not recommend OTC uses for these products in pediatric patients <2 years of age and recommends to use with caution in pediatric patients ≥2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous, as hydrochloride:

Immphentiv: 0.5 mg/5 mL (5 mL); 1 mg/10 mL (10 mL) [contains edetate (edta) disodium]

Vazculep: 10 mg/mL (1 mL [DSC], 5 mL, 10 mL) [contains sodium metabisulfite]

Generic: 10 mg/mL (1 mL, 5 mL, 10 mL)

Solution, Intravenous, as hydrochloride [preservative free]:

Biorphen: 0.5 mg/5 mL (5 mL)

Biorphen: 0.5 mg/5 mL (5 mL [DSC]) [sulfate free]

Generic: 10 mg/mL (1 mL, 5 mL, 10 mL)

Solution, Oral, as hydrochloride:

Sudafed PE Childrens: 2.5 mg/5 mL (118 mL) [alcohol free, sugar free; contains edetate (edta) disodium, fd&c red #40 (allura red ac dye), sodium benzoate; berry flavor]

Tablet, Oral, as hydrochloride:

FT Nasal Decongestant PE: 10 mg [pseudoephedrine free; contains fd&c red #40 (allura red ac dye)]

Medi-Phenyl: 5 mg [pseudoephedrine free; contains fd&c red #40 (allura red ac dye), fd&c yellow #6 (sunset yellow)]

Non-Pseudo Sinus Decongestant: 10 mg [contains fd&c red #40(allura red ac)aluminum lake, fd&c yellow #6(sunset yellow)alumin lake]

Sudafed PE Sinus Congestion: 10 mg [contains fd&c red #40(allura red ac)aluminum lake, fd&c yellow #6(sunset yellow)alumin lake, quinoline (d&c yellow #10) aluminum lake]

Sudanyl PE: 5 mg [antihistamine free, caffeine free, salt free, sugar free; contains fd&c red #40 (allura red ac dye), fd&c yellow #6 (sunset yellow)]

Generic: 10 mg

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Biorphen Intravenous)

0.5 mg/5 mL (per mL): $1.20

Solution (Immphentiv Intravenous)

0.5 mg/5 mL (per mL): $1.20

1 mg/10 mL (per mL): $1.20

Solution (Phenylephrine HCl (Pressors) Intravenous)

10 mg/mL (per mL): $1.36 - $4.80

Solution (Sudafed PE Childrens Oral)

2.5 mg/5 mL (per mL): $0.05

Solution (Vazculep Intravenous)

10 mg/mL (per mL): $5.30

Tablets (Phenylephrine HCl Oral)

10 mg (per each): $0.04

Tablets (Sudafed PE Sinus Congestion Oral)

10 mg (per each): $0.41

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Injection, as hydrochloride:

Neo-Synephrine: 10 mg/mL ([DSC]) [contains sodium metabisulfite]

Generic: 10 mg/mL (1 mL, 2 mL, 5 mL, 10 mL)

Solution Prefilled Syringe, Intravenous, as hydrochloride:

Generic: 0.5 mg/10 mL (10 mL)

Administration: Adult

IV:

Hypotension/shock: May be administered via continuous infusion (after diluting); IV infusions require an infusion pump. When administering as a continuous infusion, central line administration is preferred; extravasation may cause severe ischemic necrosis. If central line is not available, may administer for a short duration (<72 hours) through a peripheral IV catheter placed in a large vein at a proximal site (eg, in or proximal to antecubital fossa). Frequent monitoring of the IV catheter site is recommended to rapidly identify extravasation (Ref). Refer to institutional policies and procedures; catheter placement/size and vasopressor concentration may vary depending on institution. Administration through midline catheters may also be an option (Ref).

Hypotension during anesthesia: Using 100 mcg/mL concentration, administer as an IV bolus over 20 to 30 seconds.

Intracavernous (off-label route): Using a 100 to 500 mcg/mL concentration, administer laterally (3 or 9 o'clock position) near the base of the penile shaft with small needles (eg, 27-gauge). May consider penile block with local anesthetic prior to administration (Ref).

Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.

Extravasation management: If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do NOT flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate phentolamine (or alternative antidote) (Ref).

Phentolamine: SUBQ: Dilute 5 to 10 mg in 10 mL NS and administer into extravasation site as soon as possible after extravasation; if IV catheter remains in place, administer initial dose IV through the infiltrated catheter; may repeat in 60 minutes if patient remains symptomatic (Ref).

Alternative to phentolamine: Nitroglycerin topical 2% ointment: Apply a 1-inch strip to the site of ischemia to cover the affected area; may repeat every 8 hours as necessary (Ref).

Administration: Pediatric

Oral: OTC products: Administer without regard to food. Administer liquid formulation using an accurate measuring device; do not use household tablespoon.

Parenteral:

IV bolus: 10 mg/mL solution must be diluted prior to administration; a 100 mcg/mL (0.1 mg/mL) ready-to-use formulation requiring no further dilution is also available for IV bolus administration. Administer dose over 20 to 30 seconds (Ref).

Continuous IV infusion: 10 mg/mL solution must be diluted prior to administration. Administer as a continuous infusion via an infusion pump. Central line administration is preferred; extravasation may cause severe ischemic necrosis. If central line is not available, may consider administering for a short duration through a peripheral IV catheter placed in a large vein or via intraosseous access using a more dilute solution or with a second carrier fluid (Ref). Administration into an umbilical arterial catheter is not recommended. Frequent monitoring of the IV catheter site is recommended to rapidly identify extravasation. Refer to institutional policies and procedures; catheter placement/size and vasopressor concentration may vary depending on institution.

Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do NOT flush the line; gently aspirate extravasated solution, then remove needle/cannula unless needed for IV antidote; elevate extremity; apply dry, warm compresses. Initiate phentolamine (or alternative antidote) (Ref).

Usual Infusion Concentrations: Adult

IV infusion: 10 mg in 500 mL (concentration: 20 mcg/mL) of D5W or NS, 50 mg in 500 mL (concentration: 100 mcg/mL) of NS, 100 mg in 500 mL (concentration: 200 mcg/mL) of NS, or 100 mg in 250 mL (concentration: 400 mcg/mL) of NS.

Other institutions may use concentrations of 40 mcg/mL or 160 mcg/mL; however, stability information is not available for these concentrations.

Usual Infusion Concentrations: Pediatric

IV infusion: 20 mcg/mL, 40 mcg/mL, 60 mcg/mL, 80 mcg/mL, or 400 mcg/mL.

Use: Labeled Indications

Hypotension or shock: Treatment of severe hypotension or shock that persists during and after adequate fluid volume replacement.

Hypotension during anesthesia: Treatment of vasodilation and hypotension during anesthesia.

Nasal congestion [OTC]: For the temporary relief of nasal congestion due to the common cold, sinusitis, hay fever, or upper respiratory allergies.

Use: Off-Label: Adult

Priapism, acute ischemic

Medication Safety Issues
Sound-alike/look-alike issues:

Sudafed PE may be confused with Sudafed.

Vazculep may be confused with Bloxiverz (neostigmine) due to similar packaging.

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes (adrenergic agonist, IV; pediatric liquid medications requiring measurement) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Acute Care Settings).

International issues:

Biorphen: Brand name for phenylephrine systemic [US] but is also the brand name for orphenadrine [Great Britain]

Other safety concerns:

Neo (Neo-Synephrine, a well-known but DSC brand of phenylephrine) is an error-prone stemmed/coined drug name (mistaken as neostigmine)

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Acetaminophen: May increase serum concentration of Phenylephrine (Systemic). Risk C: Monitor

Alpha1-Blockers: May decrease vasoconstricting effects of Phenylephrine (Systemic). Risk C: Monitor

Atomoxetine: May increase hypertensive effects of Sympathomimetics. Atomoxetine may increase tachycardic effects of Sympathomimetics. Risk C: Monitor

Atropine (Systemic): May increase hypertensive effects of Alpha1-Agonists. Risk C: Monitor

Benzylpenicilloyl Polylysine: Coadministration of Alpha1-Agonists and Benzylpenicilloyl Polylysine may alter diagnostic results. Management: Consider delaying skin testing until alpha1-agonists are no longer required, or use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. Risk D: Consider Therapy Modification

Bornaprine: Sympathomimetics may increase anticholinergic effects of Bornaprine. Risk C: Monitor

Bromocriptine: May increase hypertensive effects of Alpha1-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days. Risk D: Consider Therapy Modification

Cannabinoid-Containing Products: May increase tachycardic effects of Sympathomimetics. Risk C: Monitor

Chloroprocaine (Systemic): May increase hypotensive effects of Phenylephrine (Systemic). Risk C: Monitor

CloZAPine: May decrease therapeutic effects of Phenylephrine (Systemic). Risk C: Monitor

Cocaine (Topical): May increase hypertensive effects of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Risk D: Consider Therapy Modification

Dihydralazine: Sympathomimetics may decrease therapeutic effects of Dihydralazine. Risk C: Monitor

Doxofylline: Sympathomimetics may increase adverse/toxic effects of Doxofylline. Risk C: Monitor

Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May increase vasoconstricting effects of Alpha1-Agonists. Risk X: Avoid

Esketamine (Injection): May increase adverse/toxic effects of Sympathomimetics. Specifically, the risk for elevated heart rate, hypertension, and arrhythmias may be increased. Risk C: Monitor

FentaNYL: Decongestants may decrease serum concentration of FentaNYL. Risk C: Monitor

Guanethidine: May increase hypertensive effects of Sympathomimetics. Guanethidine may increase arrhythmogenic effects of Sympathomimetics. Risk C: Monitor

Hyaluronidase: May increase vasoconstricting effects of Phenylephrine (Systemic). Management: Do not use hyaluronidase to enhance the dispersion or absorption of phenylephrine. Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated. Risk D: Consider Therapy Modification

Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may decrease therapeutic effects of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose. Risk X: Avoid

Kratom: May increase adverse/toxic effects of Sympathomimetics. Risk X: Avoid

Landiolol: Sympathomimetics may decrease therapeutic effects of Landiolol. Risk C: Monitor

Levothyroxine: May increase therapeutic effects of Sympathomimetics. Sympathomimetics may increase therapeutic effects of Levothyroxine. Levothyroxine may increase adverse/toxic effects of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Risk C: Monitor

Linezolid: May increase hypertensive effects of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid. Risk D: Consider Therapy Modification

Lisuride: May increase hypertensive effects of Alpha1-Agonists. Risk X: Avoid

Melperone: May decrease therapeutic effects of Phenylephrine (Systemic). Risk C: Monitor

Metergoline: May increase adverse/toxic effects of Alpha1-Agonists. Risk C: Monitor

Monoamine Oxidase Inhibitors: May increase hypertensive effects of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Risk X: Avoid

Pergolide: May increase hypertensive effects of Alpha1-Agonists. Risk C: Monitor

Propacetamol: May increase serum concentration of Phenylephrine (Systemic). Management: Monitor patients closely for increased side effects of phenylephrine if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies. Risk C: Monitor

Solriamfetol: Sympathomimetics may increase hypertensive effects of Solriamfetol. Sympathomimetics may increase tachycardic effects of Solriamfetol. Risk C: Monitor

Sympathomimetics: May increase adverse/toxic effects of Sympathomimetics. Risk C: Monitor

Tedizolid: May increase adverse/toxic effects of Sympathomimetics. Specifically, the risk for increased blood pressure and heart rate may be increased. Risk C: Monitor

Tricyclic Antidepressants: May increase therapeutic effects of Alpha1-Agonists. Tricyclic Antidepressants may decrease therapeutic effects of Alpha1-Agonists. Risk C: Monitor

Pregnancy Considerations

Phenylephrine crosses the placenta (Ngan Kee 2009).

Outcome data are available following maternal use of phenylephrine as a decongestant (route of administration not always noted) (Aselton 1985; Heinonen 1977; Rothman 1979; Yau 2013) or for hypotension during cesarean delivery (Fitzgerald 2020; Heesen 2014; Singh 2020; Xu 2018).

Phenylephrine is available over the counter for the symptomatic relief of nasal congestion. Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy. Oral phenylephrine should be avoided during the first trimester of pregnancy due to the potential for adverse pregnancy outcomes (AAAAI/ACAAI [Dykewicz 2020]).

Untreated hypotension associated with spinal anesthesia during cesarean delivery may lead to maternal nausea, vomiting, and fetal acidosis (van Dyk 2022). Phenylephrine injection is recommended for the prevention and/or treatment of maternal hypotension associated with spinal anesthesia in patients undergoing cesarean delivery (ASA 2016; Kinsella 2018; Macones 2019; van Dyk 2022).

Breastfeeding Considerations

It is not known if phenylephrine is present in breast milk.

According to the manufacturer, the decision to breastfeed should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Dietary Considerations

Some products may contain phenylalanine and/or sodium.

Monitoring Parameters

BP (or mean arterial pressure), heart rate, cardiac output (as appropriate); intravascular volume status; creatinine and urine output; peripheral perfusion; monitor site of infusion for blanching/extravasation.

Consult individual institutional policies and procedures.

Mechanism of Action

Potent, direct-acting alpha-adrenergic agonist with virtually no beta-adrenergic activity; produces systemic arterial vasoconstriction. Such increases in systemic vascular resistance may result in dose-dependent increases in systolic and diastolic blood pressure and reductions in heart rate and cardiac output (most noticeable in patients with preexisting cardiac dysfunction).

Pharmacokinetics (Adult Data Unless Noted)

Onset of action:

Blood pressure increase/vasoconstriction: IM, SubQ: 10 to 15 minutes; IV: Immediate

Nasal decongestant: Oral: 15 to 30 minutes (Kollar 2007)

Duration:

Blood pressure increase/vasoconstriction: IM: 1 to 2 hours; IV: ~15 to 20 minutes; SubQ: 50 minutes

Nasal decongestant: Oral: ≤4 hours (Kollar 2007)

Absorption: Oral: Erratic and incomplete (Kanfer 1993)

Distribution: Vd: Initial: 26 to 61 L; Vdss: 184 to 543 L (mean: 340 L) (Hengstmann 1982)

Metabolism: Hepatic via oxidative deamination (Oral: 24%; IV: 50%); Undergoes sulfation (Oral [mostly within gut wall]: 46%; IV: 8%) and some glucuronidation; forms inactive metabolites (Kanfer 1993)

Bioavailability: Oral: ≤38% (Hengstmann 1982; Kanfer 1993)

Half-life elimination: Alpha phase: ~5 minutes; Terminal phase: 2 to 3 hours (Hengstmann 1982; Kanfer 1993)

Time to peak: Oral: 0.75 to 2 hours (Kanfer 1993)

Excretion: Urine (mostly as inactive metabolites)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AR) Argentina: Fenilefrina phoroneus;
  • (AT) Austria: Neosynephrine | Phenylephrin aguettant;
  • (AU) Australia: Amcal nasal decongestant pe | Chemists Own Sinus Relief PE | Codral relief | Decongestant PE | Maxiclear sinus relief | Neo synephrine | Nyal nasal decongestant | Nyal nasal decongestant pe | Nyal sinus relief pe | Pharmacy care nasal decongestant pe | Phenylephrine bnm | Sinutab pe sinus & pain relief | Sudafed pe | Sudafed pe nasal decongestant | Terry white chemists sinus decongestant pe | Vicks actioncold nasal relief;
  • (BD) Bangladesh: Vasculex;
  • (BE) Belgium: Fenylefrine Unimedic | Phenylephrine aguettant;
  • (CH) Switzerland: Phenylephrin aguettant | Phenylephrin labatec;
  • (CO) Colombia: Fenilefrina hcl;
  • (CZ) Czech Republic: Phenylephrine | Phenylephrine aguettant;
  • (DE) Germany: Biorphen | Phenylephrin aguettant | Phenylephrin sintetica;
  • (EE) Estonia: Biorphen;
  • (ES) Spain: Fenilefrina aguettant | Fenilefrina Altan;
  • (FI) Finland: Fenylefrin abcur | Fenylefrin aguettant | Fenylefrin stragen | Fenylefrin unimedic;
  • (FR) France: Phenylephrine aguettant | Phenylephrine medac | Phenylephrine renaudin;
  • (GB) United Kingdom: Phenylephrine;
  • (HU) Hungary: Biorphen;
  • (IE) Ireland: Phenylephrine;
  • (IT) Italy: Fenilefrina aguettant;
  • (KE) Kenya: Phenylephrine aguettant;
  • (KW) Kuwait: Phenylephrine aguettant;
  • (LV) Latvia: Biorphen;
  • (NL) Netherlands: Biorphen | Fenylefrin altan | Fenylefrine Aguettant;
  • (NO) Norway: Fenylefrin | Fenylefrin aguettant | Fenylefrin stragen | Fenylefrin unimedic;
  • (NZ) New Zealand: Ethics nasal decongestant | Sudafed pe;
  • (PH) Philippines: Sinudrin;
  • (PL) Poland: Biorphen;
  • (PR) Puerto Rico: Biorphen | Immphentiv | Medi-phenyl | Phenylephrine HCL | Sudafed pe sinus congestion | Sudogest pe;
  • (PT) Portugal: Fenilefrina Altan;
  • (QA) Qatar: Phenver | Vazculep;
  • (RO) Romania: Biorphen;
  • (SA) Saudi Arabia: Phenylephrine;
  • (SE) Sweden: Fenylefrin abcur | Fenylefrin aguettant | Fenylefrin stragen | Fenylefrin unimedic;
  • (SG) Singapore: Phenylalpha;
  • (TH) Thailand: Phenylephrine;
  • (TN) Tunisia: Phenylephrine;
  • (UG) Uganda: Phenylephrine aguettant;
  • (ZA) South Africa: Biorphen | Phenylalpha
  1. Adams C, Tucker C, Allen B, et al. Disparities in hemodynamic resuscitation of the obese critically ill septic shock patient. J Crit Care. 2017;37:219-223. doi:10.1016/j.jcrc.2016.10.004 [PubMed 27969574]
  2. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  3. American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/
  4. American Society of Anesthesiologists (ASA). Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists (ASA) task force on obstetric anesthesia and the Society for Obstetric Anesthesia and Perinatology. Anesthesiology. 2016;124(2):270-300. doi:10.1097/ALN.0000000000000935 [PubMed 26580836]
  5. American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed June 18, 2021.
  6. American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated March 2024. Accessed March 22, 2024.
  7. Aselton P, Jick H, Milunsky A, Hunter JR, Stergachis A. First-trimester drug use and congenital disorders. Obstet Gynecol. 1985;65(4):451-455. [PubMed 3982720]
  8. Baloch H, Silverberg MJ, Chulani SG, et al. The effects of phenylephrine versus norepinephrine on heart rate and rhythm in patients with septic shock: a retrospective, observational study. Am J Respir Crit Care Med. 2019;199:A6699. doi:10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A6699
  9. Beale RJ, Hollenberg SM, Vincent JL, et al. Vasopressor and Inotropic Support in Septic Shock: An Evidence Based Review. Crit Care Med. 2004;32(11)(suppl):455-465. [PubMed 15542956]
  10. Biorphen (phenylephrine) [prescribing information]. Princeton, NJ: Dr Reddy's Laboratories Inc; April 2024.
  11. Bivalacqua TJ, Allen BK, Brock G, et al. Acute ischemic priapism: an AUA/SMSNA guideline. J Urol. 2021;206(5):1114-1121. doi:10.1097/JU.0000000000002236 [PubMed 34495686]
  12. Bonfiglio MF, Dasta JF, Gregory JS, et al. High-Dose Phenylephrine Infusion in the Hemodynamic Support of Septic Shock. DICP. 1990;24(10):936-939. [PubMed 2244407]
  13. Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med. 2009;37(2):666-688. [PubMed 19325359]
  14. Cardenas-Garcia J, Schaub KF, Belchikov YG, Narasimhan M, Koenig SJ, Mayo PH. Safety of peripheral intravenous administration of vasoactive medication. J Hosp Med. 2015;10(9):581-585. doi:10.1002/jhm.2394 [PubMed 26014852]
  15. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  16. Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. MMWR Morb Mortal Wkly Rep. 2007;56(1):1-4. [PubMed 17218934]
  17. Children's Sudafed PE nasal decongestant (phenylephrine systemic) [prescribing information]. McNeil PPC.
  18. Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med. 2017;45(6):1061-1093. doi:10.1097/CCM.0000000000002425 [PubMed 28509730]
  19. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637. doi:10.1097/CCM.0b013e31827e83af [PubMed 23353941]
  20. Denkler KA, Cohen BE. Reversal of Dopamine Extravasation Injury With Topical Nitroglycerin Ointment. Plast Reconstr Surg. 1989;84(5):811-813. [PubMed 2510208]
  21. Di Gennaro JL, Mack CD, Malakouti A, et al. Use and effect of vasopressors after pediatric traumatic brain injury. Dev Neurosci. 2010;32(5-6):420-430. doi:10.1159/000322083 [PubMed 21124016]
  22. Dittrich A, Albrecht K, Bar-Moshe O, Vandendris M. Treatment of pharmacological priapism with phenylephrine. J Urol. 1991;146(2):323-324. [PubMed 1856926]
  23. Drugs for pediatric emergencies. Committee on Drugs, Committee on Drugs, 1996 to 1997, Liaison Representatives, and AAP Section Liaisons. Pediatrics. 1998;101(1):E13. [PubMed 9734990]
  24. Dykewicz MS, Wallace DV, Amrol DJ, et al; Chief Editor(s): Dykewicz MS, Wallace DV; Joint Task Force on Practice Parameters: Dinakar C, Ellis AK, Golden DBK, et al; Workgroup Contributors: Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007 [PubMed 32707227]
  25. El-Alali E, Alhmoud T. Acute ischemic colitis due to oral phenylephrine. ACG Case Rep J. 2020;7(9):e00459. doi:10.14309/crj.0000000000000459 [PubMed 33062792]
  26. Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis. Crit Care. 2021;25(1):77. doi:10.1186/s13054-021-03495-8 [PubMed 33622380]
  27. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337 [PubMed 34605781]
  28. Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.
  29. Fitzgerald JP, Fedoruk KA, Jadin SM, Carvalho B, Halpern SH. Prevention of hypotension after spinal anaesthesia for caesarean section: a systematic review and network meta-analysis of randomised controlled trials. Anaesthesia. 2020;75(1):109-121. doi:10.1111/anae.14841 [PubMed 31531852]
  30. Flancbaum L, Dick M, Dasta J, et al. A dose-response study of phenylephrine in critically ill, septic surgical patients. Eur J Clin Pharmacol. 1997;51(6):461-465. [PubMed 9112060]
  31. Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm. Last accessed November 2, 2018.
  32. Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm. Last accessed November 2, 2018.
  33. Goertz AW, Lindner KH, Seefelder C, et al. Effect of Phenylephrine Bolus Administration on Global Left Ventricular Function in Patients With Coronary Artery Disease and Patients With Valvular Aortic Stenosis. Anesthesiology. 1993;78(5):834-841. [PubMed 8489054]
  34. Gregory JS, Bonfiglio MF, Dasta JF, et al. Experience With Phenylephrine as a Component of the Pharmacologic Support of Septic Shock. Crit Care Med. 1991;19(11):1395-1400. [PubMed 1935160]
  35. Gupta VD. Chemical Stability of Phenylephrine Hydrochloride After Reconstitution in 0.9% Sodium Chloride Injection for Infusion. Int J Pharmaceut Compound. 2004;8(2):153-155
  36. Heesen M, Kölhr S, Rossaint R, Straube S. Prophylactic phenylephrine for caesarean section under spinal anaesthesia: systematic review and meta-analysis. Anaesthesia. 2014;69(2):143-165. doi:10.1111/anae.12445 [PubMed 24588024]
  37. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Inc; 1977.
  38. Hengstmann JH, Goronzy J. Pharmacokinetics of 3H-Phenylephrine in Man. Eur J Clin Pharmacol. 1982;21(4):335-341. [PubMed 7056280]
  39. Hensley N, Dietrich J, Nyhan D, Mitter N, Yee MS, Brady M. Hypertrophic cardiomyopathy: a review. Anesth Analg. 2015;120(3):554-569. [PubMed 25695573]
  40. Hollenberg SM, Ahrens TS, Annane D, et al. Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update. Crit Care Med. 2004;32(9):1928-1948. [PubMed 15343024]
  41. Immphentiv (phenylephrine hydrochloride) [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; April 2024.
  42. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  43. Jain G, Singh DK. Comparison of phenylephrine and norepinephrine in the management of dopamine-resistant septic shock. Indian J Crit Care Med. 2010;14(1):29-34. doi:10.4103/0972-5229.63033 [PubMed 20606906]
  44. Jansen JJ, Oldland AR, Kiser TH. Evaluation of phenylephrine stability in polyvinyl chloride bags. Hosp Pharm. 2014;49(5):455-457. doi:10.1310/hpj4905-455 [PubMed 24958958]
  45. Kanfer I, Dowse R, Vuma V. Pharmacokinetics of Oral Decongestants. Pharmacotherapy. 1993, 13(6, pt 2):116-28; discussion 143-6. [PubMed 7507589]
  46. Kinsella SM, Carvalho B, Dyer RA, et al; Consensus Statement Collaborators. International consensus statement on the management of hypotension with vasopressors during caesarean section under spinal anaesthesia. Anaesthesia. 2018;73(1):71-92. doi:10.1111/anae.14080 [PubMed 29090733]
  47. Kiser TH, Oldland AR, Fish DN. Stability of phenylephrine hydrochloride injection in polypropylene syringes. Am J Health-Syst Pharm. 2007;64(10):1092-1095. [PubMed 17494910]
  48. Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. J Pharm Technol. 1989;5(3):101-128. [PubMed 10318297]
  49. Kliegman RM, St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Saunders Elsevier; 2020.
  50. Kollar C, Schneider H, Waksman J, et al. Meta-Analysis of the Efficacy of Single Dose of Phenylephrine 10 Mg Compared With Placebo in Adults With Acute Nasal Congestion Due to the Common Cold.Clin Ther. 2007;29(6):1057-1070. [PubMed 17692721]
  51. Levy B, Clere-Jehl R, Legras A, et al; Collaborators. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2018;72(2):173-182. doi:10.1016/j.jacc.2018.04.051 [PubMed 29976291]
  52. Lewis T, Merchan C, Altshuler D, Papadopoulos J. Safety of the peripheral administration of vasopressor agents. J Intensive Care Med. 2019;34(1):26-33. doi:10.1177/0885066616686035 [PubMed 28073314]
  53. Macones GA, Caughey AB, Wood SL, et al. Guidelines for postoperative care in cesarean delivery: Enhanced Recovery After Surgery (ERAS) Society recommendations (part 3). Am J Obstet Gynecol. 2019;221(3):247.e1-247.e9. doi:10.1016/j.ajog.2019.04.012 [PubMed 30995461]
  54. Manaker S. Use of vasopressors and inotropes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 8, 2021.
  55. Montague DK, Jarow J, Broderick GA, et al; Members of the Erectile Dysfunction Guideline Update Panel; American Urological Association. American Urological Association guideline on the management of priapism. J Urol. 2003;170(4, pt 1):1318-1324. [PubMed 14501756]
  56. Morelli A, Ertmer C, Rehberg S, et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Crit Care. 2008;12(6):R143. doi:10.1186/cc7121 [PubMed 19017409]
  57. Munarriz R, Wen CC, McAuley I, Goldstein I, Traish A, Kim N. Management of ischemic priapism with high-dose intracavernosal phenylephrine: from bench to bedside [published corrections appear in J Sex Med. 2006;3(5):938]. J Sex Med. 2006;3(5):918-922. [PubMed 16942536]
  58. Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. Am J Health Syst Pharm. 2014;71(17):1500-1508. [PubMed 25147175]
  59. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):S729-S767. [PubMed 20956224]
  60. Ngan Kee WD, Khaw KS, Tan PE, Ng FF, Karmakar MK. Placental transfer and fetal metabolic effects of phenylephrine and ephedrine during spinal anesthesia for cesarean delivery. Anesthesiology. 2009;111(3):506-512. doi:10.1097/ALN.0b013e3181b160a3 [PubMed 19672175]
  61. Nishimura RA, Holmes DR Jr. Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med. 2004;350(13):1320-1327. [PubMed 15044643]
  62. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239-e1311. doi:10.1161/CIR.0000000000001250 [PubMed 38718139]
  63. Park MK. Park's Pediatric Cardiology for Practitioners. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.
  64. Pathan S. Potential anaphylaxis to systemic phenylephrine: a case report. Hosp Pharm. 2024;59(1):19-23. doi:10.1177/00185787231185867 [PubMed 38223868]
  65. Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: Post Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):768-86. [PubMed 20956225]
  66. Phenylephrine hydrochloride injection [prescribing information]. Eatontown, NJ: Hikma Pharmaceuticals USA Inc; June 2019.
  67. Phenylephrine hydrochloride injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; March 2018.
  68. Phenylephrine hydrochloride injection [prescribing information]. Princeton, NJ: Sandoz Inc; February 2019.
  69. Phenylephrine injection (prescribing information). Irvine, CA: Teva Parenteral Medicines; October 2008.
  70. Phillips MS. Standardizing I.V. Infusion Concentrations: National Survey Results. Am J Health Syst Pharm. 2011;68(22):2176-2182. [PubMed 22058104]
  71. Prasanna N, Yamane D, Haridasa N, Davison D, Sparks A, Hawkins K. Safety and efficacy of vasopressor administration through midline catheters. J Crit Care. 2021;61:1-4. doi:10.1016/j.jcrc.2020.09.024 [PubMed 33049486]
  72. Radosevich JJ, Patanwala AE, Erstad BL. Norepinephrine dosing in obese and nonobese patients with septic shock. Am J Crit Care. 2016;25(1):27-32. doi:10.4037/ajcc2016667 [PubMed 26724290]
  73. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45(3):486-552. [PubMed 28098591]
  74. Rothman KJ, Fyler DC, Goldblatt A, Kreidberg MB. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol. 1979;109(4):433-439. doi:10.1093/oxfordjournals.aje.a112701 [PubMed 443241]
  75. Shaddy RE, Viney J, Judd VE, McGough EC. Continuous intravenous phenylephrine infusion for treatment of hypoxemic spells in tetralogy of Fallot. J Pediatr. 1989;114(3):468-470. [PubMed 2921691]
  76. Sinclair-Pingel J, Grisso AG, Hargrove FR, Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Order Entry System [published correction appears in Hosp Pharm. 2007; 42:84-85]. Hosp Pharm. 2006;41:1102-1106.
  77. Singh PM, Singh NP, Reschke M, Ngan Kee WD, Palanisamy A, Monks DT. Vasopressor drugs for the prevention and treatment of hypotension during neuraxial anaesthesia for Caesarean delivery: a Bayesian network meta-analysis of fetal and maternal outcomes. Br J Anaesth. 2020;124(3):e95-e107. doi:10.1016/j.bja.2019.09.045 [PubMed 31810562]
  78. Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. Pharmacotherapy. 2023;43(4):321-337. doi:10.1002/phar.2794 [PubMed 36938775]
  79. Stewart JM, Munoz J, Weldon A. Clinical and physiological effects of an acute alpha-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance. Circulation. 2002;106(23):2946-2954. [PubMed 12460877]
  80. Stolz A, Efendy R, Apte Y, Craswell A, Lin F, Ramanan M. Safety and efficacy of peripheral versus centrally administered vasopressor infusion: a single-centre retrospective observational study. Aust Crit Care. 2022;35(5):506-511. doi:10.1016/j.aucc.2021.08.005 [PubMed 34600834]
  81. Sudogest (phenylephrine) [prescribing information]. Livonia, MI: Major Pharmaceuticals; May 2016.
  82. Sudogest PE (phenylephrine) [prescribing information]. Livonia, MI: Major Pharmaceuticals; April 2018.
  83. Tark BE, Messe SR, Balucani C, Levine SR. Intracerebral hemorrhage associated with oral phenylephrine use: a case report and review of the literature. J Stroke Cerebrovasc Dis. 2014;23(9):2296-2300. doi:10.1016/j.jstrokecerebrovasdis.2014.04.018 [PubMed 25156786]
  84. Tian DH, Smyth C, Keijzers G, et al. Safety of peripheral administration of vasopressor medications: a systematic review. Emerg Med Australas. 2020;32(2):220-227. doi:10.1111/1742-6723.13406 [PubMed 31698544]
  85. Tran QK, Mester G, Bzhilyanskaya V, et al. Complication of vasopressor infusion through peripheral venous catheter: a systematic review and meta-analysis. Am J Emerg Med. 2020;38(11):2434-2443. doi:10.1016/j.ajem.2020.09.047 [PubMed 33039229]
  86. Vadiei N, Daley MJ, Murthy MS, Shuman CS. Impact of norepinephrine weight-based dosing compared with non-weight-based dosing in achieving time to goal mean arterial pressure in obese patients with septic shock. Ann Pharmacother. 2017;51(3):194-202. doi:10.1177/1060028016682030 [PubMed 27886982]
  87. van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525. [PubMed 28923988]
  88. van Dyk D, Dyer RA, Bishop DG. Spinal hypotension in obstetrics: context-sensitive prevention and management. Best Pract Res Clin Anaesthesiol. 2022;36(1):69-82. doi:10.1016/j.bpa.2022.04.001 [PubMed 35659961]
  89. Vazculep (phenylephrine hydrochloride) [prescribing information]. Chesterfield, MO: Avadel Legacy Pharmaceuticals; October 2019.
  90. Vazculep (phenylephrine hydrochloride) [prescribing information]. Lenoir, NC: Exela Pharma Sciences; March 2021.
  91. Waxman MB, Bonet JF, Finley JP, et al. Effects of respiration and posture on paroxysmal supraventricular tachycardia. Circulation. 1980;62(5):1011-1020. [PubMed 7418151]
  92. Wessel DL. Managing low cardiac output syndrome after congenital heart surgery. Crit Care Med. 2001;29(10)(suppl):S220-S230. [PubMed 11593065]
  93. Wong AF, McCulloch LM, Sola A. Treatment of Peripheral Tissue Ischemia With Topical Nitroglycerin Ointment in Neonates. J Pediatr. 1992;121(6):980-983. [PubMed 1447671]
  94. Xu C, Liu S, Huang Y, Guo X, Xiao H, Qi D. Phenylephrine vs ephedrine in cesarean delivery under spinal anesthesia: a systematic literature review and meta-analysis. Int J Surg. 2018;60:48-59. doi:10.1016/j.ijsu.2018.10.039 [PubMed 30389535]
  95. Yamazaki T, Shimada Y, Taenaka N, et al. Circulatory Responses to Afterloading with Phenylephrine in Hyperdynamic Sepsis. Crit Care Med. 1982;10(7):432-435. [PubMed 7083867]
  96. Yau WP, Mitchell AA, Lin KJ, Werler MM, Hernández-Díaz S. Use of decongestants during pregnancy and the risk of birth defects. Am J Epidemiol. 2013;178(2):198-208. doi:10.1093/aje/kws427 [PubMed 23825167]
  97. Zlotnick DM, Helisch A. Recurrent stress cardiomyopathy induced by Sudafed PE. Ann Intern Med. 2012;156(2):171-172. doi:10.7326/0003-4819-156-2-201201170-00028 [PubMed 22250160]
Topic 9900 Version 704.0